Stopping or delaying disease-modifying therapy doesn’t appear to lower susceptibility to COVID-19 or the risk of complications from it. But data to date are not definitive, and decisions should be individualized.
Disease-modifying therapy for multiple sclerosis is not without risks. Since its benefits may wane as immune function diminishes with age, discontinuation is tempting. A new study gives supportive reassurance.
The 2018 guideline update includes 30 recommendations — 17 on initiating DMT treatment, 10 on switching DMT agents and three on stopping DMT. The lead author shares key takeaways.